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Stratiﬁcation
It Ain’t as “Sweet” as it Sounds*Kim A. Connelly, MBBS, PHD,yz Idan Roifman, MDzSEE PAGE 400S afety, reliability, ease of use, and relatively lowcost has placed echocardiography at the fore-front of imaging modalities utilized in the
assessment of cardiac function. Over the last 2 de-
cades, techniques to detect pre-clinical cardiac
dysfunction, such as the echocardiographic estima-
tion of myocardial strain and strain rate, have been
developed. Myocardial strain measures the deforma-
tion of tissues in response to stress (1), and speckle
tracking echocardiography (STE) has emerged as the
preferred method to estimate strain (2–4). In an effort
to determine the clinical utility of STE, the prognostic
importance of strain has been assessed in a variety of
clinical scenarios. Global longitudinal strain (GLS), as
derived from STE, has been shown to be an indepen-
dent and superior predictor of mortality when
compared with “traditional” measures of systolic
function, such as left ventricular (LV) ejection frac-
tion or wall motion score index (5,6).
Both type 1 and type 2 diabetes mellitus (DM)
represent a multisystem disorder associated with
substantial cardiovascular morbidity and mortality.
Despite being an area of intensive research, the
pathophysiology driving the disease process in pa-
tients with type 1 DM remains poorly understood, and
the approach to management has generally followed*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the yKeenan Biomedical Research Centre, Li Ka Shing Knowledge
Institute, St. Michael’s Hospital, University of Toronto, Toronto,
Ontario, Canada; and the zSunnybrook Research Institute, Schulich
Heart Program, Sunnybrook Health Sciences Centre, University of
Toronto, Toronto, Ontario, Canada. Both authors have reported that
they have no relationships relevant to the contents of this paper to
disclose.that of patients with type 2 DM, who represent a
much larger cohort. Accordingly, the application of
strain imaging to deﬁne pre-clinical ventricular
dysfunction and predict outcomes in both type 1 and
2 diabetes has garnered much interest.In this issue of iJACC, Danish investigators present
the ﬁndings of the large, cross-sectional Thousand & 1
study (7). They performed STE to measure GLS in
1,065 patients with type 1 DM without known heart
disease and compared these values with 198 age- and
sex-matched control subjects. The authors presented
multiple statistical models to validate the results. In
the unadjusted univariate model, there was a signif-
icant difference in strain between type 1 diabetic
patients and control subjects. However, after adjust-
ment for relevant cardiovascular risk factors and
medications in the multivariable model, there was no
signiﬁcant difference in GLS between type 1 diabetic
patients and control subjects. Patients were also
stratiﬁed by the degree of albuminuria, a known risk
factor for the subsequent development of heart fail-
ure (8). Univariate analysis demonstrated that GLS
was signiﬁcantly different between control subjects
and patients with albuminuria, deﬁned as micro-
albuminuric if the urinary albumin excretion rate was
between 30 and 300 mg/24 h and macroalbuminuric if
the urinary albumin excretion rate was >300 mg/24 h.
Importantly, there was no signiﬁcant difference in
GLS between the normoalbuminuria and control
groups. These results did not change signiﬁcantly on
multivariable analysis after adjustment for other
relevant factors (7).
To our knowledge, this study is the largest
assessing myocardial strain in the diabetes setting.
This is a time-consuming and challenging endeavor
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412and the authors should be commended and congrat-
ulated for this undertaking. What insights, then, are
provided by these ﬁndings? In contrast to the un-
complicated type 1 DM patients, who demonstrate
normal cardiac function in this study, there is a large
body of data demonstrating subclinical LV dysfunc-
tion as manifested by a reduction in GLS in patients
with type 2 DM despite normal LV ejection fraction—
both with and without microalbuminuria (2,9). How
can we reconcile these important differences?
Although type 1 and 2 DM are diagnosed by the
same criteria (10), the underlying pathophysiology of
cardiac dysfunction in the 2 diseases is vastly
different (11). Type 1 diabetes is the result of an ab-
solute deﬁciency of insulin, primarily as a result of
beta cell failure due to autoimmune mediated
destruction. Type 2 diabetes, on the other hand, oc-
curs secondary to a variety of pathophysiological
mechanisms, including insulin resistance and beta
cell failure, typically in association with a number of
cardiovascular comorbidities, including obesity, hy-
pertension, and lipid abnormalities. The mechanisms
leading to insulin resistance and beta cell failure
remain complex, but involve abnormal hepatic, skel-
etal, lipid, and cardiac metabolism. Cardiac and beta
cell dysfunction occur as a result of impaired calcium
homeostasis, activation of the renin-angiotensin
system, altered substrate metabolism, and mito-
chondrial dysfunction. Not only do type 1 and 2 DM
differ in pathophysiology, but the response to anti-
hyperglycemic therapy differs markedly. Early and
adequate replacement of insulin with tight glycemic
control has been highly effective in reducing the
complications (including macrovascular cardiovas-
cular complications) of type 1 diabetes. Conversely,
intensive blood glucose lowering in patients withTABLE 1 Comparison of Type 1 and 2 DM
Age at onset P
Etiology T
Degree of insulin resistance þ
Obesity þ
Association of glycemic control to CVD þ
Effect of tight glycemic control on macrovascular complications þ
Relative association of CVD risk factors with CVD events




Microalbuminuria and risk of heart failure þ
þ to þþþ represents the strength of association from lowest to highest.
CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; HT ¼ hypertension; LDL ¼ lowtype 2 diabetes has been less successful in reducing
macrovascular cardiovascular complications of dia-
betes (12). Not surprisingly, then, these differing
pathophysiological mechanisms may lead to different
patterns of clinical presentation, subclinical cardiac
dysfunction, and response to therapy (Table 1).
Although in the absence of albuminuria, subclini-
cal systolic function may vary between type 1 and 2
DM, the ﬁnding that patients with type 1 DM and
albuminuria (either micro or macro) demonstrate
abnormal GLS is entirely consistent with the pub-
lished data. DM and microalbuminuria has been
shown to herald the development of heart failure (13),
and agents that modify albuminuria, such as in-
hibitors of the renin–angiotensin system, have been
shown to reduce heart failure hospitalization (8,14).
Albuminuria is regarded as a marker for widespread
endothelial damage, and it likely reﬂects disease in
both the cardiac microvascular and coronary macro-
vascular beds—thus, leading to both cardiomyocyte
dysfunction and coronary artery disease.
What are the “take home” messages from this
study and the published data regarding strain and
diabetes? First, despite similar diagnostic criteria,
patients with type 1 and 2 DM represent different
cohorts in terms of disease pathophysiology, pro-
gression, appropriate therapeutic intervention(s),
and response to therapy. Second, microalbuminuria
appears to be a robust marker for the presence of
subclinical LV dysfunction in patients with type 1 DM
and affects patient management (15); therefore, the
incremental beneﬁt for strain imaging in this cohort is
not clear. Third, although microalbuminuria is asso-
ciated with subclinical LV dysfunction in this patient
cohort, it fails to give any formal insight into disease
pathophysiology by which a speciﬁc intervention canType 1 DM Type 2 DM

















J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 4 , 2 0 1 5 Connelly and Roifman
A P R I L 2 0 1 5 : 4 1 1 – 3 Editorial Comment
413further modify cardiac and/or renal outcomes.
Finally, this study conﬁrms the current strategy of
cardiovascular protection for patients with type 1
diabetes, as it demonstrates preserved systolic and
diastolic function in a large cohort of intensively-
treated patients. Future research is required to
assess whether novel interventions over and above
renin–angiotensin system inhibition can improve
outcomes in patients with albuminuria. However, it is
vitally important that separate studies are performeddepending upon the etiology of diabetes, as the out-
comes may be very different between patients with
type 1 or 2 DM.
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